American Society of Hematology

Figure 1.

$Efficacy of 5F11-Ts. (A) Patient 10 in cohort 1 had high-burden (baseline MTV, 486.7 mL), chemotherapy-refractory cHL before 5F11-T treatment, including involvement of the left cervical lymph nodes and an enlarged hypermetabolic spleen (yellow arrows), as indicated on the pretreatment positron emission tomography-computed tomography (PET-CT) scan. (B) At day +57 after 5F11-T infusion, Patient 10’s posttreatment PET-CT scan demonstrated substantial reductions in fluorodeoxyglucose (FDG) avidity, with residual avidity present in the cervical, supraclavicular, and mediastinal nodes, and the spleen, retroperitoneum, and right pelvic wall. FDG avidity in the heart and bladder is an artifact of the test due to isotope accumulation. Patient 10 was in PR by CT criteria at this time. Lymphoma progression occurred 4 months after 5F11-T treatment. (C) Patient 15 on cohort 1 had extensive involvement of cHL before 5F11-T treatment (baseline MTV, 180.1 mL), including the sternal and left pelvic bones (yellow arrows), as shown on pretreatment PET-CT scan. (D) On day +33 after 5F11-T infusion, Patient 15 had resolution of most areas of FDG avidity, with residual avidity present in the left ilium. FDG avidity in the kidneys and bladder is an artifact of the test due to isotope accumulation. Patient 15 was in PR by CT criteria at this time. Lymphoma progression occurred 4 months after 5F11-T treatment. (E) Maximum percent change in sum of the products of the diameters (SPD) of the target lymph nodes achieved after 5F11-T infusion for each patient. The first response assessment took place 1 month after CAR T-cell infusion. The maximum percent change in SPD was achieved in all patients by 3 months after CAR T-cell infusion, or earlier. The patient with response of PD had reduction of target lesions but developed new lesions after 5F11-T infusion. (F) Duration of response in weeks of each patient, grouped by dose level. Duration of response was defined as the time from first documentation of response, including CR, PR, or SD (for patients whose best response was SD) until progression, start of new treatment, or death. Asterisks (∗) denotes a patient with response of PD. (G) Duration of response in weeks after 5F11-T infusion for patients achieving a response of PR or CR. (H) EFS in weeks after 5F11-T infusion for all patients. EFS was defined as the time from 5F11-T infusion until progression, start of new treatment, or death. (I) Overall survival in weeks after 5F11-T infusion. Overall survival was defined as the time from 5F11-T infusion until death or last follow-up.$

Efficacy of 5F11-Ts. (A) Patient 10 in cohort 1 had high-burden (baseline MTV, 486.7 mL), chemotherapy-refractory cHL before 5F11-T treatment, including involvement of the left cervical lymph nodes and an enlarged hypermetabolic spleen (yellow arrows), as indicated on the pretreatment positron emission tomography-computed tomography (PET-CT) scan. (B) At day +57 after 5F11-T infusion, Patient 10’s posttreatment PET-CT scan demonstrated substantial reductions in fluorodeoxyglucose (FDG) avidity, with residual avidity present in the cervical, supraclavicular, and mediastinal nodes, and the spleen, retroperitoneum, and right pelvic wall. FDG avidity in the heart and bladder is an artifact of the test due to isotope accumulation. Patient 10 was in PR by CT criteria at this time. Lymphoma progression occurred 4 months after 5F11-T treatment. (C) Patient 15 on cohort 1 had extensive involvement of cHL before 5F11-T treatment (baseline MTV, 180.1 mL), including the sternal and left pelvic bones (yellow arrows), as shown on pretreatment PET-CT scan. (D) On day +33 after 5F11-T infusion, Patient 15 had resolution of most areas of FDG avidity, with residual avidity present in the left ilium. FDG avidity in the kidneys and bladder is an artifact of the test due to isotope accumulation. Patient 15 was in PR by CT criteria at this time. Lymphoma progression occurred 4 months after 5F11-T treatment. (E) Maximum percent change in sum of the products of the diameters (SPD) of the target lymph nodes achieved after 5F11-T infusion for each patient. The first response assessment took place 1 month after CAR T-cell infusion. The maximum percent change in SPD was achieved in all patients by 3 months after CAR T-cell infusion, or earlier. The patient with response of PD had reduction of target lesions but developed new lesions after 5F11-T infusion. (F) Duration of response in weeks of each patient, grouped by dose level. Duration of response was defined as the time from first documentation of response, including CR, PR, or SD (for patients whose best response was SD) until progression, start of new treatment, or death. Asterisks (∗) denotes a patient with response of PD. (G) Duration of response in weeks after 5F11-T infusion for patients achieving a response of PR or CR. (H) EFS in weeks after 5F11-T infusion for all patients. EFS was defined as the time from 5F11-T infusion until progression, start of new treatment, or death. (I) Overall survival in weeks after 5F11-T infusion. Overall survival was defined as the time from 5F11-T infusion until death or last follow-up.

This Feature Is Available To Subscribers Only